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   ABSTRACT 
  Objectives      Evaluate relationships between MRI and 
clinical/laboratory/radiographic ﬁ  ndings in rheumatoid 
arthritis (RA).   
  Methods    637  methotrexate-naive  patients 
(GO-BEFORE) and 444 patients with active RA despite 
methotrexate (GO-FORWARD) were randomly assigned 
to subcutaneous placebo + methotrexate, golimumab 
100mg + placebo, golimumab 50mg + methotrexate, 
or golimumab 100mg + methotrexate every-4-weeks. 
In GO-BEFORE(n=318) and GO-FORWARD(n=240) 
substudies, MRI of dominant wrist/metacarpophalangeal 
joints were scored for synovitis, bone oedema and bone 
erosion (RA MRI scoring (RAMRIS) system). Relationships 
between RAMRIS scores and serum C-reactive protein 
(CRP), 28-joint count disease activity score (DAS28–CRP) 
and van der Heijde modiﬁ  ed Sharp (vdH-S) scores were 
assessed.  
  Results      Baseline and weeks 24/28 DAS28–CRP, CRP, 
and vdH-S generally correlated well with baseline 
and week 24 RAMRIS synovitis, oedema and erosion 
scores. Early (week 4) CRP changes correlated with later 
(week 12) RAMRIS synovitis/oedema change scores; 
earlier (week 12) changes in some RAMRIS scores 
correlated with later (weeks 24/28) changes in vdH-S. 
Signiﬁ  cant correlations between RAMRIS change scores 
and clinical/radiographic change scores were weak.   
  Conclusions    MRI  and  clinical/laboratory/radiographic 
measures generally correlated well. Associations 
between earlier changes in CRP and later changes in 
RAMRIS synovitis/osteitis were observed. Changes in 
MRI and clinical/radiographic measures did not correlate 
well, probably because MRI is more sensitive than 
radiographs  and  more  objective  than  DAS28–CRP.       
  MRI is more sensitive than radiographs in detect-
ing joint erosions    1     –      6    in rheumatoid arthritis (RA). 
Unlike radiographs, MRI can detect synovitis and 
bone marrow oedema, pre-erosive inﬂ  ammatory 
changes that increase the risk of new erosions.    7     –      13    
Areas of bone appearing as osteitis/bone marrow 
oedema by MRI are heavily inﬁ  ltrated by inﬂ  am-
matory cells and osteoclasts.    14    The detection and 
treatment of pre-erosive inﬂ  ammatory changes    10        15    
are crucial to limiting generally irreversible osseous 
joint damage.    16    
  We have reported the results of radiographic 
and MRI assessments from two large phase III tri-
als (GO-BEFORE, methotrexate-naive patients;    17     –      19    
GO-FORWARD, patients with inadequate response 
to methotrexate therapy)    18        20        21    that evaluated the 
efﬁ  cacy of golimumab (a human monoclonal anti-
body to tumour necrosis factor alpha) in RA. MRI 
ﬁ  ndings correlate with clinical, laboratory, imag-
ing and histological measures of inﬂ  ammation in 
RA.    15         16    While MRI appears more sensitive than 
radiographs in detecting bone erosion, the abil-
ity of the RA MRI scoring (RAMRIS) system to 
detect erosive changes earlier/more often than the 
van der Heijde modiﬁ  cation of the Sharp(vdH-S) 
scoring systems and the relationship between 
RAMRIS scores and laboratory/clinical measures 
of inﬂ  ammation in large randomised clinical trials 
(eg, GO-BEFORE and GO-FORWARD MRI sub-
studies) need to be assessed. 
  PATIENTS  AND  METHODS 
  Patients (318 GO-BEFORE, 240 GO-FORWARD) 
enrolled at willing and capable sites participated in 
MRI substudies.    19        21    Disease activity was assessed 
using serum C-reactive protein (CRP) concentra-
tions and 28-joint count disease activity score 
(DAS28) (calculated using CRP; DAS28 hereafter) 
scores.    22    Structural damage (bone erosion, joint 
space narrowing) was measured using vdH-S 
scores.    18        23    Preliminary assessments of relation-
ships between RAMRIS synovitis, bone oedema 
(osteitis) and bone erosion scores and DAS28 
scores, CRP levels and total vdH-S scores were 
accomplished by the determination of Spearman 
correlation coefﬁ  cients (r  s  ) for all treatment groups 
combined.  
  RESULTS 
  Baseline  patient  characteristics 
  Methotrexate-naive patients appeared to have 
more active inﬂ  ammation but less structural dam-
age than patients with an inadequate response to 
methotrexate (  table 1  ).     
  Cross-sectional  data  correlations 
    DAS28 versus RAMRIS scores 
  In GO-BEFORE, signiﬁ   cant (p<0.01) correlations 
were observed between baseline DAS28 scores and 
baseline RAMRIS synovitis (r  s  =0.40), bone oedema/
osteitis (r  s  =0.18), and bone erosion (r  s  =0.21) scores 
(  table 2  ). Signiﬁ   cant (p<0.001) correlations were 
also observed between week 24 DAS28 scores and 
week 24 RAMRIS synovitis (r  s  =0.30), bone oedema/
osteitis (r  s  =0.22) and bone erosion (r  s  =0.23) scores. 
Correlations in GO-FORWARD were weak.     
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    Serum CRP concentration versus RAMRIS scores 
  In GO-BEFORE, signiﬁ  cant (p<0.001) correlations were observed 
between baseline CRP concentrations and baseline RAMRIS syn-
ovitis (r  s  =0.36), bone oedema/osteitis (r  s  =0.37) and bone erosion 
(r  s  =0.30) scores. Signiﬁ  cant but weaker correlations were observed 
between week 24 CRP concentrations and week 24 RAMRIS 
scores. Correlations observed in GO-FORWARD were weak.   
    vdH-S versus RAMRIS scores 
  In GO-BEFORE, signiﬁ  cant (p<0.001) correlations were observed 
between baseline total vdH-S and baseline RAMRIS synovi-
tis (r  s  =0.26), bone oedema/osteitis (r  s  =0.49) and bone erosion 
(r  s  =0.64;   ﬁ  gure 1A  ) scores. Similar signiﬁ  cant correlations were 
observed between week 28 total vdH-S and week 24 RAMRIS 
scores (  ﬁ  gure 1B  ). Correlations between vdH-S and RAMRIS 
erosion scores were signiﬁ  cant (p<0.001) and strong at baseline 
(r  s  =0.58) and weeks 24/28 (r  s  =0.59). 
  In GO-FORWARD, signiﬁ   cant (p<0.001) correlations were 
observed between total vdH-S and RAMRIS synovitis (r  s  =0.28), 
bone oedema/osteitis (r  s  =0.53) and bone erosion (r  s  =0.77) base-
line scores. Findings were consistent at week 24. Correlations 
between vdH-S and RAMRIS erosion scores were   signiﬁ  cant 
(p<0.001) and strong at baseline (r  s  =0.73) and week 24 (r  s  =0.71).     
  Change  score  correlations 
    DAS28 versus RAMRIS change scores 
  Changes from baseline to week 12 and week 24 in DAS28 scores 
paralleled changes from baseline to week 12 and week 24, respec-
tively, in each RAMRIS score for GO-BEFORE and for RAMRIS 
bone oedema/osteitis scores only for GO-FORWARD (  table 2  ). 
The association between RAMRIS change scores at week 12 and 
later changes in clinical response (week 24  DAS28) was signiﬁ  -
cant only for the RAMRIS synovitis score in GO-BEFORE and 
  Table  1         Baseline clinical characteristics of the GO-BEFORE and 
GO-FORWARD MRI substudy populations   
 Characteristic 
  All MRI substudy patients 
 GO-BEFORE  
(methotrexate-naive) 
 GO-FORWARD
  (methotrexate 
inadequate response) 
Patients randomly assigned 
to treatment, n
318 240
Women, n (%) 257 (80.8%) 200 (83.3%)
  Median (IQR)
Age (years) 50.0 (41.0–58.0) 51.0 (43.0–58.0)
Disease duration (years) 1.2 (0.6–3.7) 6.3 (3.0–13.5)
Swollen joints (0–66) 10.0 (7.0–16.0) 10.0 (7.0–18.0)
Tender joints (0–68) 23.5 (13.0–35.0) 21.0 (11.0–31.0)
CRP (mg/dl) 1.2 (0.5–2.7) 0.8 (0.4–2.0)
ESR (mm/h) 38.0 (22.0–58.0) 36.0 (22.0–50.0)
DAS28 score (0–10) 5.5 (4.8–6.3) 5.3 (4.5–6.03)
  Mean±SD
Median (IQR)
Total vdH-S score (0–448) 20.5±38.1
5.5 (2.0–21.5)
36.2±46.8
15.8 (2.5–50.8)
RAMRIS scores
Synovitis, wrist plus 
MCP (0–21)*
9.5±5.0
9.5 (5.5–13.5)
7.0±4.3
7.0 (3.5–9.5)
Bone oedema/osteitis (0–69) 10.0±10.0
6.5 (2.5–15.5)
6.9±9.1
2.0 (0.0–10.7)
Bone erosion (0–230) 21.2±23.7
14.5 (10.0–22.5)
24.4±28.1
13.9 (6.5–29.5)
      Data are presented for all treatment groups combined.
*Several sites did not have the capability to obtain postgadolinium images of both the 
wrist and the metacarpophalangeal joints; therefore, RAMRIS synovitis scores are 
summarised and assessed for the subgroups of patients with both determinations. 
  CRP, C-reactive protein; DAS28, 28-joint disease activity score calculated using CRP; 
ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; RAMRIS, rheumatoid 
arthritis MRI scoring system; vdH-S, van der Heijde modiﬁ  ed Sharp score.     
  Table  2         Spearman correlation coefﬁ  cients and p values for the relationship between RAMRIS scores and clinical, laboratory and radiographic ﬁ  ndings   
 
 GO-BEFORE    (methotrexate-naive)   GO-FORWARD    (methotrexate  inadequate  response) 
 Synovitis* 
 Bone  oedema 
(osteitis)   Bone  erosions   Synovitis* 
 Bone  oedema 
(osteitis)   Bone  erosions 
Baseline RAMRIS vs:
Baseline DAS28 0.40 (p<0.001) 0.18 (p=0.002) 0.21 (p<0.001) 0.17 (p=0.021) 0.00 (p=0.96) −0.02 (p=0.741)
Baseline CRP 0.36 (p<0.001) 0.37 (p<0.001) 0.30 (p<0.001) 0.27 (p<0.001) 0.21 (p=0.002) 0.13 (p=0.065)
Baseline total vdH-S 0.26 (p<0.001) 0.49 (p<0.001) 0.64 (p<0.001) 0.28 (p<0.001) 0.53 (p<0.001) 0.77 (p<0.001)
Baseline vdH-S erosion score – – 0.58 (p<0.001) – – 0.73 (p<0.001)
Week 24 RAMRIS vs:
Week 24 DAS28 0.30 (p<0.001) 0.22 (p<0.001) 0.23 (p<0.001) 0.15 (p=0.05) 0.00 (p=0.96) 0.01 (p=0.89)
Week 24 CRP 0.24 (p<0.001) 0.25 (p<0.001) 0.23 (p<0.001) 0.21 (p=0.009) 0.02 (p=0.84) −0.02 (p=0.83)
Weeks 24/28 total vdH-S 0.25 (p<0.001) 0.48 (p<0.001) 0.65 (p<0.001) 0.47 (p<0.001) 0.54 (p<0.001) 0.76 (p<0.001)
Weeks 24/28 vdH-S erosion score – – 0.59 (p<0.001) – – 0.71 (p<0.001)
RAMRIS Δ to week 12 vs:
DAS28 Δ to week 12 0.21 (p=0.001) 0.17 (p=0.008) 0.14 (p=0.028) 0.14 (p=0.08) 0.21 (p=0.004) 0.01 (p=0.87)
DAS28 Δ to week 24 0.21 (p=0.002) 0.10 (p=0.14) 0.08 (p=0.22) 0.21 (p=0.008) 0.18 (p=0.013) 0.02 (p=0.83)
CRP %Δ to week 4 −0.17 (p=0.010) −0.13 (p=0.040) −0.005 (p=0.94) −0.23 (p=0.002) −0.19 (p=0.007) 0.06 (p=0.39)
CRP %Δ to week 12 −0.21 (p=0.002) −0.19 (p=0.002) −0.05 (p=0.45) −0.22 (p=0.005) −0.20 (p=0.006) −0.04 (p=0.54)
Total vdH-S Δ to weeks 24/28 0.08 (p=0.22) 0.14 (p=0.033) 0.05 (p=0.48) 0.16 (p=0.07) 0.10 (p=0.23) −0.18 (p=0.027)
vdH-S erosion score Δ to weeks 24/28 – – 0.03 (p=0.59) – – −0.15 (p=0.07)
RAMRIS Δ to week 24 vs:
DAS28 Δ to week 24 0.22 (p<0.001) 0.13 (p=0.036) 0.17 (p=0.006) 0.36 (p<0.001) 0.21 (p=0.008) 0.10 (p=0.22)
CRP %Δ to week 24 −0.20 (p=0.002) −0.25 (p<0.001) −0.06 (p=0.34) −0.32 (p<0.001) −0.22 (p=0.007) −0.03 (p=0.69)
Total vdH-S Δ to weeks 24/28 0.13 (p=0.06) 0.07 (p=0.31) 0.03 (p=0.63) 0.12 (p=0.22) 0.16 (p=0.09) −0.06 (p=0.50)
vdH-S erosion score Δ to weeks 24/28 – – 0.07 (p=0.28) – – −0.03 (p=0.75)
      Data are presented for all treatment groups combined. 
  *Several sites did not have the capability to obtain postgadolinium images of both the wrist and the metacarpophalangeal joints; therefore, RAMRIS synovitis scores are summarised 
and assessed for the subgroups of patients with both determinations. 
  CRP, C-reactive protein; DAS28, 28-joint disease activity score calculated using CRP; RAMRIS, rheumatoid arthritis MRI score; vdH-S, van der Heijde modiﬁ  ed Sharp score.     
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(an early time point) CRP change was associated with later 
changes at week 12 in synovitis and bone oedema/osteitis, but 
not bone erosion, RAMRIS scores.   
    vdH-S versus RAMRIS change scores 
  In GO-BEFORE, changes from baseline to week 12 and week 
24 in RAMRIS scores generally did not correlate with changes 
for synovitis and bone oedema/osteitis, but not bone erosion, 
RAMRIS scores in GO-FORWARD.   
    Serum CRP concentration versus RAMRIS change scores 
  Changes from baseline to week 12 and week 24 in serum 
CRP concentrations paralleled RAMRIS synovitis and bone 
oedema/osteitis, but not bone erosion, change scores. Week 4 
 Figure  1        Relationship between Rheumatoid Arthritis MRI Scoring (RAMRIS) system bone erosion scores and total van der Heijde-modiﬁ  ed Sharp 
(vdH-S) scores for absolute scores at baseline (A), absolute scores at week 24/28 (B), and changes in scores from baseline to week 24/28 (C) in the 
GO-BEFORE study. Observed data are presented for all treatment groups combined.    
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Anti-tumour necrosis factor agents dramatically inhibit radio-
graphic progression; thus, the association between RAMRIS-
detected changes in structural damage and vdH-S scores may 
best be assessed in control groups with the possibility of further 
progression. This was not the case for GO-FORWARD, as mini-
mal progression was observed in all patients regardless of treat-
ment.    18 21     The lack of strong concordance between RAMRIS 
bone erosion and vdH-S (total and erosion) change scores may 
also be related to RAMRIS measuring the wrist plus metacar-
pophalangeal joints of one hand, while the total vdH-S scoring 
incorporates joints of both hands and feet. As the total vdH-S 
score includes the joint space narrowing subscore, while the 
RAMRIS score does not, an analysis to evaluate the correlation 
of changes in the vdH-S erosion subscore only and in RAMRIS 
erosion scores was conducted; these results also did not indicate 
good correlation. Finally, wide individual variation was observed 
in change scores, again possibly implicating insufﬁ  cient sample 
size and little radiographic or MRI-detectable progression of 
structural damage in GO-FORWARD.    18        21    Interestingly, even 
though the MRI and clinical/radiographic change scores did not 
correlate well in either GO-BEFORE or GO-FORWARD, the 
overall results of these MRI substudies were consistent with 
radiographic ﬁ  ndings in the overarching study populations. 
  Taken together, ﬁ   ndings derived from GO-BEFORE and 
GO-FORWARD MRI substudies indicate that RAMRIS scores 
and clinical/laboratory/radiographic measures at certain 
time points (ie, baseline, week 24) generally correlate well. 
For change scores, only changes in CRP correlated well with 
RAMRIS changes. The lack of strong/consistent correlations 
between vdH-S/DAS28 change scores and RAMRIS change 
scores is probably related to differential sensitivities of MRI and 
x-ray for detecting erosive changes, the subjective component 
of DAS28, wide individual variations in reporting joint tender-
ness, and analysing all patients regardless of treatment group. 
Further in-depth analyses beyond this preliminary examination 
are underway to understand fully the relationship between MRI 
assessments and other measures of disease activity/progression 
of structural damage and the value of MRI in clinical practice 
and trials.             
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from baseline to week 28 in total vdH-S score (  ﬁ  gure 1C  ), with 
the exception of a statistically signiﬁ  cant but weak correlation 
between week 12 RAMRIS bone oedema/osteitis and week 28 
total vdH-S change scores (r  s  =0.14, p=0.033). In GO-FORWARD, 
week 24 RAMRIS change scores did not correlate with week 24 
total vdH-S change scores. However, week 12 RAMRIS bone 
erosion changes weakly predicted later changes at week 24 in 
total vdH-S scores (r  s  =−0.18, p=0.027). Correlations between 
vdH-S erosion and RAMRIS erosion change scores were not 
signiﬁ  cant in either study.       
  DISCUSSION 
  Consistent with previous reports,    15        16    in our preliminary assess-
ment of MRI data derived from the largest randomised, con-
trolled trials evaluating RAMRIS scores in RA patients, we 
observed strong and signiﬁ  cant correlations of cross-sectional 
data at baseline and week 24 between RAMRIS bone erosion 
and total vdH-S radiographic scores and between RAMRIS bone 
erosion and vdH-S erosion scores. At both baseline and week 
24 of GO-BEFORE, statistically signiﬁ   cant correlations were 
observed between each RAMRIS score and DAS28 scores and 
between each RAMRIS score and CRP concentrations. Overall, 
the correlations between RAMRIS scores and evaluated clinical/
laboratory/radiographic measures indicated that MRI ﬁ  ndings 
represent disease activity and structural damage status as mea-
sured by conventional methods, thus conﬁ  rming the ﬁ  ndings of 
previously reported smaller studies and anecdotal reports.    15        16    
  Interestingly, clinical/radiographic change scores generally 
did not correlate well with RAMRIS change scores. Changes 
in CRP, however, did correlate well with changes in RAMRIS 
measures of inﬂ  ammation (synovitis and bone oedema/osteitis). 
In particular, early (week 4) changes in CRP may predict future 
changes in RAMRIS scores. The relatively stronger correlation 
observed between CRP and MRI change scores could be due 
to the objectivity of these measures. The DAS28 change score 
(clinical measure of disease activity) generally did not correlate 
well with RAMRIS change scores, perhaps because of the com-
posite nature of the DAS28, which includes the subjective ten-
der joint count not measured by MRI. In particular, if tenderness 
is due to factors beyond inﬂ  ammation (eg, higher pain percep-
tion of the patient, ﬁ  bromyalgia, etc), the DAS28 score may not 
correlate with RAMRIS measures of inﬂ  ammation depending on 
the relative contribution of the tender joint count to the DAS28 
score. While persistently high DAS28 scores predispose patients 
to more structural damage progression, the actual degree of 
progression varies widely across patients. Furthermore, in 
GO-FORWARD both RAMRIS and radiographic structural dam-
age progression were minimal in all treatment arms including the 
control arm. Given the wide variability in patients’ responses (as 
measured by DAS28) to therapeutic interventions and that only 
a small proportion of patients showed structural progression, a 
much larger sample size (than was available in these substud-
ies) may have been needed to study such correlations, or lack 
thereof, adequately in these RA assessment tools. We also con-
ducted post-hoc analyses using only the control arm to eliminate 
the possible impact of golimumab treatment on change scores, 
and results were similar to those described above. However, the 
much smaller sample size (approximately 25% less than analy-
ses involving all treatment arms combined) in these analyses 
should be considered in interpreting these post-hoc results. 
  The lack of strong correlation between RAMRIS erosion 
and vdH-S change scores could be due to the higher sensitiv-
ity of MRI versus radiographs in detecting bone erosion.    1     –      6        19    
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